On March 9, 2026, Pulse Biosciences, Inc. announced long-term follow-up data from its nPulse™ system study, which showed a 74% average volume reduction in treated benign thyroid nodules over 15-22 months, with high patient satisfaction reported. This event occurred at the North American Society for Interventional Thyroidology meeting on March 6, 2026.